摘要
结外NK/T细胞淋巴瘤(ENKTCL)是异质性强、高度侵袭性的非霍奇金淋巴瘤。尽管大多数ENKTCL患者诊断时为早期,但由于分期的局限性,预后差异较大。放疗和化疗是早期ENKTCL患者的一线治疗方法,但放疗、化疗模式及治疗时序仍存在争议。随着临床分期及预后模型的不断更新,早期ENKTCL患者倾向于接受风险适应性分层治疗。本文回顾性分析近年来分期、预后模型以及治疗相关的最新研究结果,以期为临床决策的制定提供参考依据。
Extranodal natural killer/T-cell lymphoma(ENKTCL)is the subtype of non-Hodgkin lymphoma with high heterogeneity and invasiveness.Though most ENKTCL patients are present as early-stage at diagnosis,clinical prognosis significantly differs due to the limitations of clinical staging.Radiotherapy(RT)and chemotherapy(CT)are the first-line treatments for early ENKTCL patients.However,there is no consensus on the combined modalities of RT and CT,and their optimal strategy.With the continuous renewal of clinical staging and prognostic models,early-stage ENKTCL patients tend to accept risk-adapted treatment with proper stratification.In this review,the latest research progresses on clinical staging,prognostic models and treatment were retrospectively analyzed,aiming to provide references for clinical decision-making.
作者
许恬
尹丽
詹梦娜
胡新宇
薛珂
裴帅
何侠
Xu Tian;Yin Li;Zhan Mengna;Hu Xinyu;Xue Ke;Pei Shuai;He Xia(Affiliated Cancer Hospital of Nanjing Medical University&Jiangsu Cancer Hospital&Jiangsu Institute of Cancer Research,Nanjing 210009,China;Fourth School of Clinical Medicine,Nanjing Medical University,Nanjing 210000,China;Xuzhou Medical University,Xuzhou 221000,China)
出处
《中华放射肿瘤学杂志》
CSCD
北大核心
2021年第6期631-636,共6页
Chinese Journal of Radiation Oncology
基金
江苏省科技厅重点研发计划(BE2019756)
江苏省卫生健康委员会科教强卫工程项目(十三五)(QNRC2016648)。
